After offering perception into the outcomes of the STEP 1 and STEP 3 trials, Dr. Wadden discusses who he believes the accountability for prescribing these drugs will fall unto if semaglutide receives approval as a weight reduction agent.
Because the push for extra strong and a larger number of weight problems remedies reaches a fever pitch, the dialog has begun to evolve and embrace the query about who ought to be accountable for prescribing new drugs for weight loss.
Whereas the reply for years has been clinicians specializing in bariatric surgical procedure, the explosion in weight problems prevalence has meant that accountability now extends to different specialties, together with endocrinology, inside drugs, and typically cardiologists. With subcutaneous semaglutide showing promise in the STEP program and up for FDA approval as early as June, this query is being pushed to the forefront.
STEP 1, which randomized overweight sufferers to semaglutide plus life-style intervention or place, indicated the two.4 mg dose of semaglutide was related to a 14.9% discount in physique weight and 86.4% of sufferers receiving the GLP1-RA achieved weight lack of 5% or extra. In STEP 3, which included a extra intense life-style intervention, outcomes demonstrated a 16% discount in physique weight with semaglutide and instructed greater than 75% of members receiving semaglutide noticed reductions in physique weight of 10% or larger.
For extra perspective on who ought to be answerable for partaking with these sufferers and initiating remedy with an agent like subcutaneous semaglutide, Endocrinology Community reached out to Thomas Wadden, PhD, professor of Psychology on the Perelman College of Drugs and principal investigator within the STEP program.